Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
about
The spectrum of SWI/SNF mutations, ubiquitous in human cancersTunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.A landscape of driver mutations in melanomaExome sequencing identifies recurrent somatic RAC1 mutations in melanomaERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?New developments in dermatological oncogeneticsThree-stage quality control strategies for DNA re-sequencing dataPathways and therapeutic targets in melanomaMelanoma: from mutations to medicineA genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencingSomatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxinGuanine holes are prominent targets for mutation in cancer and inherited diseaseImpact of the next-generation sequencing data depth on various biological result inferences.Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma.Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention.KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.FBXW7 mutations in melanoma and a new therapeutic paradigmA meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.A highly recurrent RPS27 5'UTR mutation in melanoma.Melanoma: clinical features and genomic insights.Genome resequencing and bioinformatic analysis of SNP containing candidate genes in the autoimmune vitiligo Smyth line chicken model.Driving toward targeted therapy for LCH.Exome sequencing generates high quality data in non-target regions.Cancer genomics and pathology: all together now.Sleeping giants: emerging roles for the fat cadherins in health and disease.Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing.Prospective enterprise-level molecular genotyping of a cohort of cancer patients.The MAPK pathway across different malignancies: a new perspective.Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patientsDriver mutations in melanoma: lessons learned from bench-to-bedside studiesGenotyping of cutaneous melanoma.Genomic Classification of Cutaneous MelanomaComprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profilingCancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma.TET proteins and the control of cytosine demethylation in cancer.
P2860
Q54901939-1997D05E-9B3B-41A5-B705-B5D63EAC901EQ54901941-C7769471-4AE3-483E-8161-BC9700F6613FQ54901949-7681E4E2-220C-4B21-937C-98E6DC00940FQ54901951-0997F62B-450D-4556-AEA0-58652987FAEBQ54901972-B8AE2519-E322-4E9D-A8E0-09F21722B1EFQ54901979-698E0D02-851E-4C33-809A-C38015394E5AQ54901980-CFA8C765-09F0-45DF-9D3F-85A9646B9CF7
P1343
Q21090801-C82A0AAE-2818-4175-8728-D9FCB18680DBQ24315032-271A23E8-978B-47A1-81C8-48725EE439A9Q24603357-3C1A6B06-987A-47E6-84C2-DD7505035A29Q24607661-833F84F8-6DFE-477A-A384-2CB53F2013E8Q26744787-7FA09BED-F964-4445-AF75-C020916A04CAQ26853582-F6F4180D-02BD-44FB-800A-ED2286B94C9BQ26864378-B16934EF-7E49-4B7C-9CC5-03580614BB22Q26865736-AB205522-4EBC-4B0F-B7DE-B09184E77E19Q27024061-4D7838DF-61C5-4B70-A7D9-382FBC9F30E6Q27852431-CFBDB67D-B07A-44C6-9DBD-55F585F1A3F7Q28275103-2688625C-BFE5-4AC6-A032-41A993B8EB36Q28397328-CFAF0F63-B168-439E-BEF7-57553DC88C09Q28533852-5E5AD326-5D7B-4A2C-8343-7085154073F2Q30587393-2C397C20-B5CA-445A-9EE3-CF524581CBDEQ33618850-61133780-D12E-4F77-8971-957EB0E83F03Q33772624-C0A79500-A1C8-4D7F-A6CB-FC93C73C663FQ33809921-DE55FF48-9C9A-468F-97E4-46578DFC0E86Q33845217-8C03E58B-24DE-4EDC-AEC1-DB7A9145D9EAQ33875566-5D2DC93C-4575-4E28-A301-5DF388E5BB1DQ33884726-A913C863-F5C7-4621-B773-E580DC8737ECQ33917519-E1A843E0-42E2-4000-AD72-7A14F1404B69Q34083191-99DDDF2B-5EB7-4EA1-BD08-40AFB12AE2CEQ34123644-ABB5B31F-4269-4738-B7A9-011CB322C45AQ34136966-6A02A2AE-F670-40C5-80C2-1E1A12B14162Q34274291-D2405F58-C6D4-4AC0-B588-10EB3827321DQ34301519-C96F3651-56E6-40FC-BA10-619E63FCFBA9Q34347563-BB8F72E0-34C0-4C30-BD20-1AE2610A880EQ34362611-00FB0980-DE6E-48D4-B48C-E1C6FDA4177FQ34362617-2E6482A9-31EA-47E8-A9CB-321ADF569193Q34409739-D9F31C4C-5E23-4E73-A6FD-007E98CCF2EBQ34459097-D7F3A85A-75C6-4840-BA5C-C37E1997B75BQ34471813-963183C7-A5E4-47ED-ACB3-0DC85847BD44Q34622439-64F51E2B-6E0F-4285-B310-45BCE36046A9Q34626018-33199621-2840-4C1B-935A-651627498B7AQ34639532-A5087F7F-3199-47EF-822B-DE75E3896506Q34667738-11BD9DF6-1E1C-486D-8150-62AEA6E3DB62Q34670776-4291A461-7BE9-4F55-952D-429D6E77A512Q34737562-119C33C1-AF43-4ACD-AD5F-81F562C35080Q34983791-3A7CC840-CCBC-41FF-A0A0-143E4F4AE3A0Q35021377-12782357-BC42-4E3A-ADE0-24302C031EED
P2860
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
@en
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
@nl
type
label
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
@en
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
@nl
prefLabel
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
@en
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
@nl
P2093
P2860
P4510
P50
P356
P1433
P1476
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
@en
P2093
Brian J Stevenson
Corinne Gehrig
Daniel Robyr
Daniel Speiser
Donata Rimoldi
Katja Muehlethaler
Keith Harshman
Michel Guipponi
Olesya Bukach
Olivier Michielin
P2860
P2888
P304
P356
10.1038/NG.1026
P407
P50
P577
2011-12-25T00:00:00Z